Ipilimumab and nivolumab for cancer treatment: a pharmacovigilance study based on the FDA adverse event reporting system database - Poll - MDSpire

Ipilimumab and nivolumab for cancer treatment: a pharmacovigilance study based on the FDA adverse event reporting system database

  • By

  • Ruming Liu

  • Yaoyu Xiang

  • Xidan Hu

  • Min Zhang

  • Lujie Wang

  • Tao Liu

  • Xi Wang

  • Bin Qian

  • June 18, 2026

  • 0 min

Share

Original Source(s)

Ipilimumab and nivolumab for cancer treatment: a pharmacovigilance study based on the FDA adverse event reporting system database

  • by Ruming Liu, Yaoyu Xiang, Xidan Hu, Min Zhang, Lujie Wang, Tao Liu, Xi Wang, Bin Qian

  • June 18, 2026

Related Content

ABO gene polymorphisms: a molecular bridge linking disease susceptibility to therapeutic outcomes

The regulatory roles of dysregulated lactate dehydrogenase A in anti-tumor immunity within immune cells

Clinical outcomes of tebentafusp in metastatic uveal melanoma: a systematic review and single-arm meta-analysis